Genscript Biotech (HKSE:01548) Inventories, Finished Goods : HK$217 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Inventories, Finished Goods?

Genscript Biotech's quarterly finished goods declined from Dec. 2022 (HK$191 Mil) to Jun. 2023 (HK$165 Mil) but then increased from Jun. 2023 (HK$165 Mil) to Dec. 2023 (HK$217 Mil).

Genscript Biotech's annual finished goods increased from Dec. 2021 (HK$165 Mil) to Dec. 2022 (HK$191 Mil) and increased from Dec. 2022 (HK$191 Mil) to Dec. 2023 (HK$217 Mil).

Genscript Biotech Inventories, Finished Goods Historical Data

The historical data trend for Genscript Biotech's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Inventories, Finished Goods Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

82.99

108.37

165.00

191.13

217.05

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Finished Goods	Get a 7-Day Free Trial														165.00	-	191.13	164.85	217.05

Genscript Biotech Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Executives

Wang Luquan	2401 A concert party to an agreement to buy shares
Wang Ye	2101 Beneficial owner
Zhang Fangliang	2401 A concert party to an agreement to buy shares
Huang Lili	2202 Interest of your spouse
Hu Zhiyong	2201 Interest of corporation controlled by you
Jin Weihong	2201 Interest of corporation controlled by you
Genscript Corporation	2101 Beneficial owner
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Gns Holdings Limited	2101 Beneficial owner
Hillhouse Capital Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines